Table 2 Changes from baseline in PASI score and severity of each symptom and area of skin lesion in patients with psoriasis of blood-heat syndrome receiving Pulian ointment or placebo
Full analysis set (FAS) | Per protocol analysis (PPS) | |||||
|---|---|---|---|---|---|---|
(Mixed Effect Model with correction) | (Mixed Effect Model with correction) | |||||
Pulian Ointment (n = 143) (Mean change) | Placebo (n = 135) (Mean change) | Effect size estimate MD (95% CI; P-value) | Pulian Ointment (n = 132) (Mean change) | Placebo (n = 128) (Mean change) | Effect size estimate MD (95% CI; P-value) | |
PASI score | ||||||
2 weeks | −1.26 | −0.98 | −0.28 (−0.70, 0.14; 0.19) | −1.35 | −0.99 | −0.36 (−0.80, 0.07; 0.10) |
4 weeks | −2.49 | −1.78 | −0.70 (−1.39, −0.02; 0.043*) | −2.51 | −1.86 | −0.65 (−1.31, 0.02; 0.056) |
Area score | ||||||
2 weeks | −0.06 | −0.03 | −0.03 (−0.08, 0.01; 0.15) | −0.07 | −0.03 | −0.04 (−0.08, 0.01; 0.14) |
4 weeks | −0.23 | −0.13 | −0.10 (−0.19, −0.02; 0.02*) | −0.17 | −0.11 | −0.06 (−0.14, 0.01; 0.09) |
Scaling score | ||||||
2 weeks | −0.15 | −0.15 | −0.00 (−0.07, 0.06; 0.96) | −0.16 | −0.15 | −0.01 (−0.08, 0.06; 0.75) |
4 weeks | −0.40 | −0.32 | −0.08 (−0.18, 0.03; 0.15) | −0.34 | −0.29 | −0.05 (−0.14, 0.05; 0.32) |
Erythema score | ||||||
2 weeks | −0.19 | −0.22 | 0.03 (−0.05, 0.11; 0.43) | −0.19 | −0.21 | 0.02 (−0.05, 0.10; 0.54) |
4 weeks | −0.44 | −0.35 | −0.08 (−0.19, 0.02; 0.12) | −0.39 | −0.33 | −0.06 (−0.16, 0.05; 0.29) |
Induration/thickness score | ||||||
2 weeks | −0.19 | −0.16 | −0.02 (−0.11, 0.06; 0.59) | −0.20 | −0.16 | −0.04 (−0.12, 0.05; 0.39) |
4 weeks | −0.42 | −0.36 | −0.06 (−0.18, 0.05; 0.29) | −0.35 | −0.33 | −0.02 (−0.12, 0.09; 0.72) |